Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 91Neoplasm Metastasis 24Neoplasms 14Brain Neoplasms 13Prostatic Neoplasms 10Endometrial Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Ovarian Neoplasms 7Glioblastoma 7Glioma 6Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Colorectal Neoplasms 5Sarcoma 4Recurrence 4Pancreatic Neoplasms 4Lymphoma, Non-Hodgkin 4Sarcoma, Ewing 3Osteosarcoma 3Neoplasms by Site 3Multiple Myeloma 3Meningioma 3Melanoma 3Liposarcoma 3Carcinoma, Renal Cell 3Breast Diseases 3Unilateral Breast Neoplasms 2Rhabdomyosarcoma 2Rhabdoid Tumor 2

Interventions

lutetium Lu 177 dotatate 6lanreotide 4Octreotide 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4pasireotide 3copper dotatate CU-64 3gallium Ga 68 dotatate 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Nivolumab 2Magnetic Resonance Spectroscopy 2Lutetium-177 2Lutetium 2Irinotecan 2Ga(III)-DOTATOC 2Everolimus 2Etoposide 2Carboplatin 2zimberelimab 1regorafenib 1pembrolizumab 1irinotecan sucrosofate 1folfirinox 1famitinib 1cabozantinib 1arginyllysine 1abemaciclib 1X-Rays 1Sunitinib 1Somatostatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gastro-enteropancreatic neuroendocrine tumor × abemaciclib × Clear all
NCT03891784 2026-01-14

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

University of Washington

Phase 2 Active not recruiting
20 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡